The COPS6 antibody targets the COP9 signalosome subunit 6 (COPS6), a critical component of the evolutionarily conserved COP9 signalosome (CSN) complex. The CSN complex, composed of eight subunits (CSN1-CSN8), regulates the ubiquitin-proteasome system by interacting with cullin-RING ubiquitin ligases (CRLs). Specifically, COPS6 (also known as CSN6) plays a regulatory role in maintaining the stability and activity of CRLs, which are essential for protein degradation, cell cycle progression, DNA repair, and stress responses. Dysregulation of COPS6 has been linked to cancer, immune disorders, and neurodegenerative diseases due to its impact on protein homeostasis and signaling pathways like NF-κB and p53.
Antibodies against COPS6 are widely used in research to study its expression, localization, and interaction partners. They are essential tools in techniques such as Western blotting, immunoprecipitation, and immunofluorescence. COPS6 antibodies help elucidate its role in modulating substrate ubiquitination, cellular proliferation, and apoptosis. Studies using these antibodies have revealed COPS6’s oncogenic potential, as overexpression is observed in various cancers, correlating with poor prognosis. Additionally, COPS6 antibodies aid in exploring post-translational modifications and regulatory mechanisms of the CSN complex, providing insights into therapeutic targeting of diseases associated with ubiquitin-mediated proteolysis.